Skip to content Skip to navigation

Pharmaceuticals

Antares Pharma Products

The complaint for this class action alleges that Antares Pharma provided false or misleading information about one of its drugs in the Food and Drug Administration (FDA) approval process, implying that it was likely to receive approval, and leading to a quick drop in its stock price when the FDA rejected it. The complaint alleges that the company’s statements were false and misleading because they did not disclose Antares had not given the FDA enough data for the drug, and that it was therefore being overly optimistic about its approval prospects.

Oxycontin Bottle and Pills

The complaint for this class action alleges that the makers of opioids have deceptively promoted the drugs, minimizing the dangers of addiction, the tolerance that requires increasing dosages, and the sometimes-lethal side effects. Their efforts are described in a fifty-page complaint with extensive footnotes: the development of misleading literature and advertisements on opioids, the deployment of sales agents to push opioids, the persuading of seemingly neutral groups to develop educational materials and treatment guidelines, and the recruiting of doctors to give paid speeches, draft misleading studies, present deceptive educational programs, and otherwise act as “key opinion leaders” in favor of opioids.

Oxycontin Bottle and Pills

Our country has an opioid epidemic.

Opioid Painkillers

According to the complaint for this class action, drug companies who promoted the use of opioids for chronic pain have created enormous problems for the state and people of Arkansas. The complaint claims that, previously, opioids were only for short-term use for acute pain, such as during recovery from surgery, or for end-of-life care. Sometime in the 1990s, it alleges, drug makers began to deceptively promote the use of opioids for chronic pain, through marketing materials as well as “unbranded advertising disseminated by seemingly independent third parties” that minimized the likelihood of addiction and the difficulty of withdrawal.

These lawsuits allege that Merck violated state law in the marketing of its drug Januvia as the company failed to warn of increased risk of pancreatic cancer.

Pages